S:CORT researchers have demonstrated for the first time how molecular analysis of clinical trial biopsy samples can be used to help clinicians identify the key changes that occur in an individual patient’s bowel (colorectal) tumour prior to surgery, so clinicians can better understand and treat the disease.
Researchers from Queen’s University Belfast and the University of Leeds, as part of a pan-European partnership called the European Cancer Concord (ECC) ®, have won the prestigious 2018 European Health Award.
This award honours initiatives that help tackle some of Europe’s most pressing health challenges.
The award-winning project, entitled ‘The European Cancer Patient’s Bill of Rights: A Catalyst for Change and an empowerment tool for cancer patients across Europe’ involves an equal partnership between cancer patients, healthcare professionals and cancer researchers.
Professor Mark Lawler, Vice President of the European Cancer Concord (ECC), today received the award on behalf of ECCO during the opening ceremony of the European Health Forum Gastein, the premier European Health Policy Conference and an official event of the Austrian European Council Presidency.
To read the full paper, click here.
Susan Richman from the Leeds Institute of Cancer and Pathology obtained £1120 from the Medical Research Council (MRC) to fund a stand at the MRC’s Festival of Medical Research. The stand titled, ‘So, just what is personalised Medicine?’ was split into three sections, with the first aiming to bust the stigma around bowel cancer screening, incorporating a game and a competition.